ImmunityBio/$IBRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Ticker
$IBRX
Sector
Primary listing
Employees
688
Headquarters
Website
ImmunityBio Metrics
BasicAdvanced
$8.2B
-
-$0.38
0.02
-
Price and volume
Market cap
$8.2B
Beta
0.02
52-week high
$12.43
52-week low
$1.83
Average daily volume
35M
Financial strength
Current ratio
5.099
Quick ratio
4.622
Long term debt to equity
-167.219
Total debt to equity
-169.088
Interest coverage (TTM)
-2.28%
Profitability
EBITDA (TTM)
-226.602
Gross margin (TTM)
99.34%
Net profit margin (TTM)
-310.18%
Operating margin (TTM)
-213.64%
Effective tax rate (TTM)
0.04%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-36.17%
Return on equity (TTM)
71.17%
Valuation
Price to revenue (TTM)
65.039
Price to book
-16.19
Price to tangible book (TTM)
-15.75
Price to free cash flow (TTM)
-23.831
Free cash flow yield (TTM)
-4.20%
Free cash flow per share (TTM)
-0.336
Growth
Revenue change (TTM)
668.31%
Earnings per share change (TTM)
-38.27%
3-year revenue growth (CAGR)
678.62%
3-year earnings per share growth (CAGR)
-28.42%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
ImmunityBio News
AllArticlesVideos
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug
Benzinga·2 days ago
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
Business Wire·2 weeks ago
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $8.2B as of March 11, 2026.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of March 11, 2026.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of March 11, 2026.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of 0.02. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.